Mainz Biomed announced that it has submitted its application to the FDA requesting breakthrough device designation for its non-invasive next generation colorectal cancer, or CRC, product including the company’s novel portfolio of mRNA biomarkers. Subject to the FDA’s review, a breakthrough device designation could significantly accelerate approval.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYNZ:
- Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
- Mainz Biomed provides half-year corporate update
- Mainz Biomed Provides Half Year 2024 Corporate Update
- Mainz Biomed presents data from pooled study at ASCO 2024
- Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024